The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2013Effect of Glitazone Antidiabetic Medication on the Risk of Parkinson’s Disease
Objective/Rationale:
Several biological processes are thought to cause Parkinson’s disease. One involves inflammation within the central nervous system, but so far, no treatments are... -
Access Data and Biospecimens, 2013Environmental Determinants of Expressivity and Penetrance in LRRK2 Parkinsonism
Objective/Rationale:
We will investigate the role of environmental factors on likelihood of developing Parkinson’s disease (PD) and the severity of the disease in parkinsonism associated... -
Rapid Response Innovation Awards, 2013The Role of Noncoding RNAs in Parkinson’s Disease
Objective/Rationale:
Recent genome-wide association studies comparing the DNA of thousands of healthy people with the DNA of Parkinson’s patients showed regions of the human genome that... -
Rapid Response Innovation Awards, 2013Is Mitochondrial Hemoglobin Reduced in Parkinson’s Disease Brain?
Objective/Rationale:
Mitochondria are undergoing scrutiny by researchers trying to understand Parkinson’s disease (PD). We have discovered that the oxygen-carrying protein hemoglobin is found in... -
Research Grant, 2013Is ATP13A2 a Lysosomal Lipid Flippase that Affects Alpha-synuclein Membrane Interactions?
Promising Outcomes of Original Grant:
One of the objectives of the original study was the development of biochemical and cell-based assays for measuring ATP13A2 protein activity. We largely achieved... -
Synuclein Therapeutic Acceleration Program, 2013Immunotherapy with Alpha-synuclein Specific Antibody
Objective/Rationale:
The protein alpha-synuclein is believed to play a major role in the development of Parkinson’s disease (PD). Toxic forms of alpha-synuclein can cause neuronal...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.